Technology
Health
Pharmaceutical
Neos Therapeutics
$3.019876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$3.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.15 (5.24%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell NEOS and other stocks, options, ETFs, and crypto commission-free!
About
Neos Therapeutics, Inc. Common Stock, also called Neos Therapeutics, is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Read More Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX.
Employees
215
Headquarters
Grand Prairie, Texas
Founded
1994
Market Cap
142.07M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
362.76K
High Today
$3.13
Low Today
$2.85
Open Price
$2.90
Volume
724.27K
52 Week High
$8.70
52 Week Low
$1.40
Collections
Technology
Health
Pharmaceutical
Therapy
Manufacturing
2015 IPO
US
North America
News
Simply Wall StMar 25
What Kind Of Investor Owns Most Of Neos Therapeutics, Inc. (NASDAQ:NEOS)?
A look at the shareholders of Neos Therapeutics, Inc. (NASDAQ:NEOS) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Warren Buffett said that he likes ‘a business with enduring competitive advantages that is run by able and owner-oriented people’. So it’s nice to see some insider ownership, because it may suggest that management is owner-oriented. Neos Therapeutics is ...
Guru FocusMar 18
Neos Therapeutics Inc (NEOS) Files 10-K for the Fiscal Year Ended on December 31, 2018
Neos Therapeutics Inc (NASDAQ:NEOS) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies.
Seeking AlphaMar 14
Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q4 2018 Results - Earnings Call Transcript
Neos Therapeutics, Inc. (NASDAQ:NEOS) Q4 2018 Results Conference Call March 14, 2019 9:30 AM ET Company Participants Richard Eisenstadt - CFO Jerry McLaughlin - CEO Conference Call Participants Louise Chen - Cantor Fitzgerald Jason Butler - JMP Securities Bill Maughan - Cowen and Company Gary Nachman - BMO Capital Markets Jacob Hughes - Wells Fargo Operator Good morning. And welcome to the Neos Therapeutics' Fourth Quarter and Full Year 2018 Financial Results Conference Call. Today's call is bein...
Price Paid on Robinhood
0% Lower
Right Now
52 Week Low
$1.40
Average Price Paid
$3.02
52 Week High
$8.70
Earnings
-$0.83
-$0.63
-$0.43
-$0.23
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.28 per share
Actual
-$0.23 per share